Antiarrhythmic drug therapy of atrial fibrillation

Cardiology Clinics

Volumn 22, Issue 1, 2004, Pages 21-34

  VerNooy, Robert A ^a   Mounsey, J Paul ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DEETHYLAMIODARONE; DIGOXIN; DIHYDROPYRIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DISOPYRAMIDE; DOFETILIDE; FLECAINIDE; IBUTILIDE; MAGNESIUM; PLACEBO; POTASSIUM CHANNEL; PROCAINAMIDE; PROPAFENONE; QUINIDINE; SODIUM CHANNEL AFFECTING AGENT; SOTALOL; TRANDOLAPRIL; WARFARIN;

ALLERGIC PNEUMONITIS; ANOREXIA; ANTICHOLINERGIC EFFECT; ATAXIA; BLINDNESS; BRADYCARDIA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONSTIPATION; CORNEA INJURY; DISEASE EXACERBATION; DIZZINESS; DRUG MECHANISM; DYSPNEA; EPIDIDYMITIS; ERECTILE DYSFUNCTION; FATIGUE; FIBROSIS; GASTROINTESTINAL DISEASE; GLAUCOMA; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART PREEXCITATION; HEART PROARRHYTHMIA; HEPATITIS; HUMAN; HYPERTHYROIDISM; HYPERTROPHIC CARDIOMYOPATHY; HYPOTENSION; HYPOTHYROIDISM; INOTROPISM; LIVER CIRRHOSIS; LUPUS ERYTHEMATOSUS; MAINTENANCE THERAPY; MORTALITY; NAUSEA; OPTIC NERVE DISEASE; PARESTHESIA; PERIPHERAL NEUROPATHY; PHOTOPHOBIA; PHOTOSENSITIVITY; PNEUMONIA; PREGNANCY; PRIORITY JOURNAL; PROSTATISM; REVIEW; SKIN DISCOLORATION; SODIUM TRANSPORT; TACHYCARDIA; TORSADE DES POINTES; TOXICITY; URINE RETENTION; VISUAL DISORDER; XEROSTOMIA;

EID: 1642518218     PISSN: 07338651     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0733-8651(03)00116-4     Document Type: Review

References (109)

1. AFFIRM Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) investigators. N Engl J Med. 347:2002;1825-1833.
2. Vaughan Williams E.M. Subgroups of class 1 antiarrhythmic drugs. Eur Heart J. 5:(2):1984;96-98.
3. Dorian P., Naccarelli G.V., Coumel P., Hohnloser S.H., Maser M.J. A randomized comparison of flecainide versus verapamil in paroxysmal supraventricular tachycardia. The Flecainide Multi-center Investigators Group. Am J Cardiol. 77:(3):1996;89A-95A.
4. UK Propafenone PSVT Study Group. A randomized, placebo-controlled trial of propafenone in the prophylaxis of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation. Circulation. 92:(9):1995;2550-2557.
5. Hohnloser S.H., Zabel M. Short- and long-term efficacy and safety of flecainide acetate for supraventricular arrhythmias. Am J Cardiol. 70:(5):1992;3A-9A.
6. Anderson J.L., Platt M.L., Guarnieri T., Fox T.L., Maser M.J., Pritchett E.L. Flecainide acetate for paroxysmal supraventricular tachyarrhythmias. The Flecainide Supraventricular Tachycardia Study Group. Am J Cardiol. 74:(6):1994;578-584.
7. Anderson J.L., Gilbert E.M., Alpert B.L., Henthorn R.W., Waldo A.L., Bhandari A.K., et al. Prevention of symptomatic recurrences of paroxysmal atrial fibrillation in patients initially tolerating antiarrhythmic therapy. A multi-center, double-blind, crossover study of flecainide and placebo with transtelephonic monitoring. Flecainide Supraventricular Tachycardia Study Group. Circulation. 80:(6):1989;1557-1570.
8. Antman E.M., Beamer A.D., Cantillon C., McGowan N., Goldman L., Friedman P.L. Long-term oral propafenone therapy for suppression of refractory symptomatic atrial fibrillation and atrial flutter. J Am Coll Cardiol. 12:(4):1988;1005-1011.
9. Pritchett E.L., McCarthy E.A., Wilkinson W.E. Propafenone treatment of symptomatic paroxysmal supraventricular arrhythmias. A randomized, placebo-controlled, cross-over trial in patients tolerating oral therapy. Ann Intern Med. 114:(7):1991;539-544.
10. Reimold S.C., Maisel W.H., Antman E.M. Propafenone for the treatment of supraventricular tachycardia and atrial fibrillation: a meta-analysis. Am J Cardiol. 82:1998;66N-71N.
11. Echt D.S., Liebson P.R., Mitchell L.B., Peters R.W., Obias-Manno D., Barker A.H., et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med. 324:(12):1991;781-788.
12. Capucci A., Boriani G. Propafenone in the treatment of cardiac arrhythmias. A risk-benefit appraisal. Drug Saf. 12:(1):1995;55-72.
13. Hughes M.M., Trohman R.G., Simmons T.W., Castle L.W., Wilkoff B.L., Morant V.A., et al. Flecainide therapy in patients treated for supraventricular tachycardia with near normal left ventricular function. Am Heart J. 123:(2):1992;408-412.
14. Fuster V., Ryden L.E., Asinger R.W., Cannom D.S., Crijns H.J., Frye R.L., et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients with Atrial Fibrillation). Developed in Collaboration with the North American Society of Pacing and Electrophysiology. J Am Coll Cardiol. 38:(4):2001;1231- 1266.
15. Miller M.R., McNamara R.L., Segal J.B., Kim N., Robinson K.A., Goodman S.N., et al. Efficacy of agents for pharmacologic conversion of atrial fibrillation and subsequent maintenance of sinus rhythm: a meta-analysis of clinical trials. J Fam Pract. 49:(11):2000;1033-1046.
16. Grey E., Silverman D.I. Efficacy of type 1C antiarrhythmic agents for treatment of resistant atrial fibrillation. Pacing Clin Electrophysiol. 16:(12):1993;2235-2240.
17. Rae A.P. Placebo-controlled evaluations of propafenone for atrial tachyarrhythmias. Am J Cardiol. 82:(8A):1998;59N-65N.
18. Anderson J.L., Jolivette D.M., Fredell P.A. Summary of efficacy and safety of flecainide for supraventricular arrhythmias. Am J Cardiol. 62:(6):1988;62D-66D.
19. Jung F., DiMarco J.P. Treatment strategies for atrial fibrillation. Am J Med. 104:(3):1998;272-286.
20. Boriani G., Martignani C., Biffi M., Capucci A., Branzi A. Oral loading with propafenone for conversion of recent-onset atrial fibrillation: a review on in-hospital treatment. Drugs. 62:(3):2002;415-423.
21. Anderson J.L., Prystowsky E.N. Sotalol: an important new antiarrhythmic. Am Heart J. 137:(3):1999;388-409.
22. Waldo A.L., Camm A.J., deRuyter H., Freidman P.L., MacNeil D.J., Pitt B., et al. Survival with oral d-sotalol in patients with left ventricular dysfunction after myocardial infarction: rationale, design, and methods (the SWORD trial). Am J Cardiol. 75:(15):1995;1023-1027.
23. Waldo A.L., Camm A.J., deRuyter H., Friedman P.L., MacNeil D.J., Pauls J.F., et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival with oral d-sotalol. Lancet. 348:(9019):1996;7-12.
24. Pratt C.M., Camm A.J., Cooper W., Friedman P.L., MacNeil D.J., Moulton K.M., et al. Mortality in the Survival With ORal D-sotalol (SWORD) trial: why did patients die? Am J Cardiol. 81:(7):1998;869-876.
25. Julian D.G., Jackson F.S., Szekely P., Prescott R.J. A controlled trial of sotalol for 1 year after myocardial infarction. Circulation. 67:1983;I61-I62.
26. Southworth M.R., Zarembski D., Viana M., Bauman J. Comparison of sotalol versus quinidine for maintenance of normal sinus rhythm in patients with chronic atrial fibrillation. Am J Cardiol. 83:(12):1999;1629-1632.
27. Benditt D.G., Williams J.H., Jin J., Deering T.F., Zucker R., Browne K., et al. Maintenance of sinus rhythm with oral d, l-sotalol therapy in patients with symptomatic atrial fibrillation and/or atrial flutter. d, l-Sotalol Atrial Fibrillation/Flutter Study Group. Am J Cardiol. 84:(3):1999;270-277.
28. Juul-Moller S., Edvardsson N., Rehnqvist-Ahlberg N. Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation. Circulation. 82:(6):1990;1932-1939.
29. Reimold S.C., Cantillon C.O., Friedman P.L., Antman E.M. Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. Am J Cardiol. 71:(7):1993;558-563.
30. Roy D., Talajic M., Dorian P., Connolly S., Eisenberg M.J., Green M., et al. Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. N Engl J Med. 342:(13):2000;913-920.
31. de Paola A.A., Veloso H.H. Efficacy and safety of sotalol versus quinidine for the maintenance of sinus rhythm after conversion of atrial fibrillation. SOCESP Investigators. The Cardiology Society of Sao Paulo. Am J Cardiol. 84:(9):1999;1033-1037.
32. Reiffel J.A. Impact of structural heart disease on the selection of class III antiarrhythmics for the prevention of atrial fibrillation and flutter. Am Heart J. 135:(4):1998;551-556.
33. Ben David J., Zipes D.P., Ayers G.M., Pride H.P. Canine left ventricular hypertrophy predisposes to ventricular tachycardia induction by phase 2 early after depolarizations after administration of BAY K 8644. J Am Coll Cardiol. 20:(7):1992;1576-1584.
34. Lehmann M.H., Hardy S., Archibald D., Quart B., MacNeil D.J. Sex difference in risk of Torsades de Pointes with d, l-sotalol. Circulation. 94:(10):1996;2535-2541.
35. Wolbrette D.L. Risk of proarrhythmia with class III antiarrhythmic agents: sex-based differences and other issues. Am J Cardiol. 91:(6A):2003;39D-44D.
36. Carmeliet E. Voltage- and time-dependent block of the delayed K + current in cardiac myocytes by dofetilide. J Pharmacol Exp Ther. 262:(2):1992;809-817.
37. Falk R.H., Pollak A., Singh S.N., Friedrich T. Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter. Intravenous Dofetilide Investigators. J Am Coll Cardiol. 29:(2):1997;385-390.
38. Singh S., Zoble R.G., Yellen L., Brodsky M.A., Feld G.K., Berk M., et al. Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the symptomatic atrial fibrillation investigative research on dofetilide (SAFIRE-D) study. Circulation. 102:(19):2000;2385-2390.
39. McClellan K.J., Markham A. Dofetilide: a review of its use in atrial fibrillation and atrial flutter. Drugs. 58:(6):1999;1043-1059.
40. Torp-Pedersen C., Moller M., Bloch-Thomsen P.E., Kober L., Sandoe E., Egstrup K., et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N Engl J Med. 341:(12):1999;857-865.
41. Kober L., Bloch Thomsen P.E., Moller M., Torp-Pedersen C., Carlsen J., Sandoe E., et al. Effect of dofetilide in patients with recent myocardial infarction and left-ventricular dysfunction: a randomised trial. Lancet. 356:(9247):2000;2052-2058.
42. Pedersen O.D., Bagger H., Keller N., Marchant B., Kober L., Torp-Pedersen C. Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: a Danish investigations of arrhythmia and mortality on dofetilide (diamond) substudy. Circulation. 104:(3):2001;292-296.
43. Mounsey J.P., DiMarco J.P. Cardiovascular drugs. Dofetilide. Circulation. 102:(21):2000;2665-2670.
44. Zarembski D.G., Nolan P.E. Jr., Slack M.K., Caruso A.C. Treatment of resistant atrial fibrillation. A meta-analysis comparing amiodarone and flecainide. Arch Intern Med. 155:(17):1995;1885-1891.
45. Van Noord T., Van Gelder I.C., Schoonderwoerd B.A., Crijns H.J. Immediate reinitiation of atrial fibrillation after electrical cardioversion predicts subsequent pharmacologic and electrical conversion to sinus rhythm and amiodarone. Am J Cardiol. 86:(12):2000;1384-1385.
46. Goldschlager N., Epstein A.E., Naccarelli G., Olshansky B., Singh B. Practical guidelines for clinicians who treat patients with amiodarone. Practice Guidelines Subcommittee, North American Society of Pacing and Electrophysiology. Arch Intern Med. 160:(12):2000;1741-1748.
47. Jafari-Fesharaki M., Scheinman M.M. Adverse effects of amiodarone. Pacing Clin Electrophysiol. 21:1998;108-120.
48. Vorperian V.R., Havighurst T.C., Miller S., January C.T. Adverse effects of low dose amiodarone: a meta-analysis. J Am Coll Cardiol. 30:(3):1997;791-798.
49. Amiodarone Trials Meta-Analysis Investigators. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials. Lancet. 350:(9089):1997;1417-1424.
50. Coplen S.E., Antman E.M., Berlin J.A., Hewitt P., Chalmers T.C. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials. Circulation. 82:(4):1990;1106-1116.
51. Flaker G.C., Blackshear J.L., McBride R., Kronmal R.A., Halperin J.L., Hart R.G. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators. J Am Coll Cardiol. 20:(3):1992;527-532.
52. Grace A.A., Camm A.J. Quinidine. N Engl J Med. 338:(1):1998;35-45.
53. Stambler B.S., Wood M.A., Ellenbogen K.A. Comparative efficacy of intravenous ibutilide versus procainamide for enhancing termination of atrial flutter by atrial overdrive pacing. Am J Cardiol. 77:(11):1996;960-966.
54. Volgman A.S., Carberry P.A., Stambler B., Lewis W.R., Dunn G.H., Perry K.T., et al. Conversion efficacy and safety of intravenous ibutilide compared with intravenous procainamide in patients with atrial flutter or fibrillation. J Am Coll Cardiol. 31:(6):1998;1414-1419.
55. Karlson B.W., Torstensson I., Abjorn C., Jansson S.O., Peterson L.E. Disopyramide in the maintenance of sinus rhythm after electroconversion of atrial fibrillation. A placebo-controlled 1-year follow-up study. Eur Heart J. 9:(3):1988;284-290.
56. Crijns H.J., Gosselink A.T., Lie K.I. Propafenone versus disopyramide for maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation: a randomized, double-blind study. PRODIS Study Group. Cardiovasc Drugs Ther. 10:(2):1996;145-152.
57. Channer K.S. Current management of symptomatic atrial fibrillation. Drugs. 61:(10):2001;1425-1437.
58. Maron B.J. Hypertrophic cardiomyopathy: a systematic review. JAMA. 287:(10):2002;1308-1320.
59. Bauman J.L., Gallastegui J., Strasberg B., Swiryn S., Hoff J., Welch W.J., et al. Long-term therapy with disopyramide phosphate: side effects and effectiveness. Am Heart J. 111:(4):1986;654-660.
60. Tieleman R.G., Van Gelder I.C., Crijns H.J., De Kam P.J., Van Den Berg M.P., Haaksma J., et al. Early recurrences of atrial fibrillation after electrical cardioversion: a result of fibrillation-induced electrical remodeling of the atria? J Am Coll Cardiol. 31:1998;167-173.
61. Falk R.H., Knowlton A.A., Bernard S.A., Gotlieb N.E., Battinelli N.J. Digoxin for converting recent-onset atrial fibrillation to sinus rhythm. A randomized, double-blinded trial. Ann Intern Med. 106:(4):1987;503-506.
62. Robles de Medina E.O., Algra A. Digoxin in the treatment of paroxysmal atrial fibrillation. Lancet. 354:(9182):1999;882-883.
63. Jordaens L., Trouerbach J., Calle P., Tavernier R., Derycke E., Vertongen P., et al. Conversion of atrial fibrillation to sinus rhythm and rate control by digoxin in comparison to placebo. Eur Heart J. 18:(4):1997;643-648.
64. Pedersen O.D., Bagger H., Kober L., Torp-Pedersen C. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation. 100:(4):1999;376- 380.
65. Madrid A.H., Bueno M.G., Rebollo J.M., Marin I., Pena G., Bernal E., et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. Circulation. 106:(3):2002;331-336.
66. Prystowsky E.N. Inpatient versus outpatient initiation of antiarrhythmic drug therapy for patients with supraventricular tachycardia. Clin Cardiol. 17:1994;II7-II10.
67. Hauser T.H., Pinto D.S., Josephson M.E., Zimetbaum P. Safety and feasibility of a clinical pathway for the outpatient initiation of antiarrhythmic medications in patients with atrial fibrillation or atrial flutter. Am J Cardiol. 91:(12):2003;1437-1441.
68. Slavik R.S., Tisdale J.E., Borzak S. Pharmacologic conversion of atrial fibrillation: a systematic review of available evidence. Prog Cardiovasc Dis. 44:(2):2001;121-152.
69. Sager P.T. New advances in class III antiarrhythmic drug therapy. Curr Opin Cardiol. 15:(1):2000;41-53.
70. Lau C.P., Lok N.S. A comparison of transvenous atrial defibrillation of acute and chronic atrial fibrillation and the effect of intravenous sotalol on human atrial defibrillation threshold. Pacing Clin Electrophysiol. 20:1997;2442-2452.
71. Davis D.R., Beatch G.N., Dickenson D.R., Tang A.S. Dofetilide enhances shock-induced extension of refractoriness and lowers defibrillation threshold. Can J Cardiol. 15:(2):1999;193-200.
72. Naccarelli G.V., Wolbrette D.L., Khan M., Bhatta L., Hynes J., Samii S., et al. Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials. Am J Cardiol. 91:(6A):2003;15D-26D.
73. Bianconi L., Mennuni M., Lukic V., Castro A., Chieffi M., Santini M. Effects of oral propafenone administration before electrical cardioversion of chronic atrial fibrillation: a placebo-controlled study. J Am Coll Cardiol. 28:(3):1996;700-706.
74. Tse H.F., Lau C.P., Ayers G.M. Incidence and modes of onset of early reinitiation of atrial fibrillation after successful internal cardioversion, and its prevention by intravenous sotalol. Heart. 82:(3):1999;319-324.
75. Wijffels M.C., Kirchhof C.J., Dorland R., Allessie M.A. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation. 92:(7):1995;1954-1968.
76. Dell'Orfano J.T., Patel H., Wolbrette D.L., Luck J.C., Naccarelli G.V. Acute treatment of atrial fibrillation: spontaneous conversion rates and cost of care. Am J Cardiol. 83:(5):1999;788-790.
77. Danias P.G., Caulfield T.A., Weigner M.J., Silverman D.I., Manning W.J. Likelihood of spontaneous conversion of atrial fibrillation to sinus rhythm. J Am Coll Cardiol. 31:(3):1998;588-592.
78. Boriani G., Capucci A., Lenzi T., Sanguinetti M., Magnani B. Propafenone for conversion of recent-onset atrial fibrillation. A controlled comparison between oral loading dose and intravenous administration. Chest. 108:(2):1995;355-358.
79. Boriani G., Biffi M., Capucci A., Botto G.L., Broffoni T., Rubino I., et al. Oral loading with propafenone: a placebo-controlled study in elderly and nonelderly patients with recent onset atrial fibrillation. Pacing Clin Electrophysiol. 21:(11 Pt 2):1998;2465-2469.
80. Suttorp M.J., Kingma J.H., Jessurun E.R., Lie A.H., van Hemel N.M., Lie K.I. The value of class IC antiarrhythmic drugs for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm. J Am Coll Cardiol. 16:(7):1990;1722-1727.
81. Azpitarte J., Alvarez M., Baun O., Garcia R., Moreno E., Martin F., et al. Value of single oral loading dose of propafenone in converting recent-onset atrial fibrillation. Results of a randomized, double-blind, controlled study. Eur Heart J. 18:(10):1997;1649-1654.
82. Botto G.L., Capucci A., Bonini W., Boriani G., Broffoni T., Barone P., et al. Conversion of recent onset atrial fibrillation to sinus rhythm using a single oral loading dose of propafenone: comparison of two regimens. Int J Cardiol. 58:(1):1997;55-61.
83. Hohnloser S.H., Li Y.G. Drug treatment of atrial fibrillation: what have we learned? Curr Opin Cardiol. 12:(1):1997;24-32.
84. Boriani G., Biffi M., Capucci A., Botto G., Broffoni T., Ongari M., et al. Conversion of recent-onset atrial fibrillation to sinus rhythm: effects of different drug protocols. Pacing Clin Electrophysiol. 21:1998;2470-2474.
85. Hughes C., Sunderji R., Gin K. Oral propafenone for rapid conversion of recent onset atrial fibrillation - a review. Can J Cardiol. 13:(9):1997;839-842.
86. Madrid A.H., Moro C., Marin-Huerta E., Mestre J.L., Novo L., Costa A. Comparison of flecainide and procainamide in cardioversion of atrial fibrillation. Eur Heart J. 14:(8):1993;1127-1131.
87. Capucci A., Boriani G., Botto G.L., Lenzi T., Rubino I., Falcone C., et al. Conversion of recent-onset atrial fibrillation by a single oral loading dose of propafenone or flecainide. Am J Cardiol. 74:(5):1994;503-505.
88. Botto G.L., Bonini W., Broffoni T., Molteni S., Lombardi R., Alfieri G., et al. Conversion of recent onset atrial fibrillation with single loading oral dose of propafenone: is in-hospital admission absolutely necessary? Pacing Clin Electrophysiol. 19:1996;1939-1943.
89. Capucci A., Villani G.Q., Piepoli M.F., Aschieri D. The role of oral 1C antiarrhythmic drugs in terminating atrial fibrillation. Curr Opin Cardiol. 14:(1):1999;4-8.
90. Falk R.H. Proarrhythmia in patients treated for atrial fibrillation or flutter. Ann Intern Med. 117:(2):1992;141-150.
91. Botto G.L., Bonini W., Broffoni T., Cappelletti G., Falcone C., Lombardi R., et al. Regular ventricular rhythms before conversion of recent onset atrial fibrillation to sinus rhythm. Pacing Clin Electrophysiol. 17:1994;2114-2117.
92. Ellenbogen K.A., Stambler B.S., Wood M.A., Sager P.T., Wesley R.C. Jr., Meissner M.C., et al. Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter: a dose-response study. J Am Coll Cardiol. 28:(1):1996;130-136.
93. Ellenbogen K.A., Clemo H.F., Stambler B.S., Wood M.A., VanderLugt J.T. Efficacy of ibutilide for termination of atrial fibrillation and flutter. Am J Cardiol. 78:1996;42-45.
94. Caron M.F., Kluger J., Tsikouris J.P., Ritvo A., Kalus J.S., White C.M. Effects of intravenous magnesium sulfate on the QT interval in patients receiving ibutilide. Pharmacotherapy. 23:(3):2003;296-300.
95. Vos M.A., Golitsyn S.R., Stangl K., Ruda M.Y., Van Wijk L.V., Harry J.D., et al. Superiority of ibutilide (a new class III agent) over DL-sotalol in converting atrial flutter and atrial fibrillation. The Ibutilide/Sotalol Comparator Study Group. Heart. 79:(6):1998;568-575.
96. Gowda R.M., Punukollu G., Khan I.A., Wilbur S.L., Vasavada B.C., Sacchi T.J. Ibutilide for pharmacological cardioversion of atrial fibrillation and flutter: impact of race on efficacy and safety. Am J Ther. 10:(4):2003;259-263.
97. Nattel S., Liu L., St Georges D. Effects of the novel antiarrhythmic agent azimilide on experimental atrial fibrillation and atrial electrophysiologic properties. Cardiovasc Res. 37:(3):1998;627-635.
98. Norgaard B.L., Wachtell K., Christensen P.D., Madsen B., Johansen J.B., Christiansen E.H., et al. Efficacy and safety of intravenously administered dofetilide in acute termination of atrial fibrillation and flutter: a multicenter, randomized, double-blind, placebo-controlled trial. Danish Dofetilide in Atrial Fibrillation and Flutter Study Group. Am Heart J. 137:(6):1999;1062-1069.
99. Kerin N.Z., Faitel K., Naini M. The efficacy of intravenous amiodarone for the conversion of chronic atrial fibrillation. Amiodarone versus quinidine for conversion of atrial fibrillation. Arch Intern Med. 156:(1):1996;49-53.
100. Tieleman R.G., Gosselink A.T., Crijns H.J., Van Gelder I.C., Van Den Berg M.P., De Kam P.J., et al. Efficacy, safety, and determinants of conversion of atrial fibrillation and flutter with oral amiodarone. Am J Cardiol. 79:(1):1997;53-57.
101. Galve E., Rius T., Ballester R., Artaza M.A., Arnau J.M., Garcia-Dorado D., et al. Intravenous amiodarone in treatment of recent-onset atrial fibrillation: results of a randomized, controlled study. J Am Coll Cardiol. 27:(5):1996;1079-1082.
102. Cybulski J., Kulakowski P., Budaj A., Danielewicz H., Maciejewicz J., Kawka-Urbanek T., et al. Intravenous amiodarone for cardioversion of recent-onset atrial fibrillation. Clin Cardiol. 26:(7):2003;329-335.
103. Nattel S., Khairy P., Roy D., Thibault B., Guerra P., Talajic M., et al. New approaches to atrial fibrillation management: a critical review of a rapidly evolving field. Drugs. 62:(16):2002;2377-2397.
104. Chow T., Galvin J., McGovern B. Antiarrhythmic drug therapy in pregnancy and lactation. Am J Cardiol. 82:1998;58I-62I.
105. Wagner X., Jouglard J., Moulin M., Miller A.M., Petitjean J., Pisapia A. Coadministration of flecainide acetate and sotalol during pregnancy: lack of teratogenic effects, passage across the placenta, and excretion in human breast milk. Am Heart J. 119:1990;700-702.
106. McKenna W.J., Harris L., Perez G., Krikler D.M., Oakley C., Goodwin J.F. Arrhythmia in hypertrophic cardiomyopathy II: Comparison of amiodarone and verapamil in treatment . Br Heart J. 46:(2):1981;173-178.
107. McKenna W.J. Arrhythmia and prognosis in hypertrophic cardiomyopathy. Eur Heart J. 4:1983;225-234.
108. Matsubara H., Nakatani S., Nagata S., Ishikura F., Katagiri Y., Ohe T., et al. Salutary effect of disopyramide on left ventricular diastolic function in hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol. 26:(3):1995;768-775.
109. Sherrid M.V., Pearle G., Gunsburg D.Z. Mechanism of benefit of negative inotropes in obstructive hypertrophic cardiomyopathy. Circulation. 97:(1):1998;41-47.